Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. David G. Maloney, MD
|
|
Give Review
David Maloney practices Oncology. He received awards:"America's Top Doctors" and "America's Top Doctors for Cancer". David G. Maloney is a published physician. He has 100 papers published. The most current publication "Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy." He accepts all Medicare patients.
Publications
- Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T Cell therapy.
- Maintenance rituximab after autologous stem Cell transplantation in patients with mantle Cell lymphoma.
- A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin Lymphoma.
- Pre-transplant comorbidity burden and post-transplant Chronic graft-versus-host disease.
- 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic Leukemia: utility of pretra...
- Alternative donors extend transplantation for patients with Lymphoma who lack an HLA matched donor.
- Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation.
- Allogeneic hematopoietic Cell transplantation for mycosis fungoides and Sezary syndrome.
- A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
- Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin Lymphoma patients can increase the proportion achieving FDG PET negative status.
- Impact of donor age on outcome after allogeneic hematopoietic Cell transplantation.
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- Early Failure of Frontline Rituximab-containing Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma does not Predict Futility of Autologous Hematopoietic Cell Transpla...
- Autologous transplant for relapsed follicular Lymphoma: impact of pre-transplant rituximab sensitivity.
- Pre-transplant comorbidities predict severity of Acute graft-versus-host disease and subsequent mortality.
- Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelody...
- Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma.
- A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.
- Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation...
- Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial.
- Autologous haematopoietic Cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
- Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation.
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic Cell transplantation.
- Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic Cell transplantation: prognostic relevance of the initial CD3+ T Cell ...
- High-Throughput Identification of Promiscuous Inhibitors from Screening Libraries with the Use of a Thiol-Containing Fluorescent Probe.
- Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil.
- Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III ...
- Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-vs.-Host Disease and Graft-vs.-Tumor Effects.
- Autologous and allogeneic transplantation for burkitt Lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transpl...
- Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-ToSitumomab for Previously Untreated Follicular Non-Hodgkin...
- Allogeneic hematopoietic Cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic Cell transplantation for advanced hematologic malignancies.
- The role of autologous and allogeneic hematopoietic stem Cell transplantation for hodgkin lymphoma.
- Hodgkin Lymphoma.
- Cytopenias after day 28 in allogeneic hematopoietic Cell transplantation: impact ofrecipient/donor factors, transplant conditions and myelotoxic drugs.
- Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic Cell transplantation.
- Decreased serum albumin as a biomarker for severe Acute graft-vs.-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving Hig...
- Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk Acute lymphoblastic leukemia.
- 90Y-ibritumomab tiuxetan, fludarabine, and TBI based non-myeloablative allogeneic transplant conditioning for patients with persistent high-risk B-Cell lymphoma.
- Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation.
- Identification of MAGE-C1 (CT-7) epitopes for T-Cell therapy of multiple myeloma.
- Stem cell transplantation for indolent lymphoma and chronic lymphocytic Leukemia.
- The B-Cell tumor-associated antigen ROR1 can be targeted with T Cells modified to express a ROR1-specific chimeric antigen receptor.
- Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic Cell transplantation.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with Acute myeloid leukemia.
- Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem Cell transplantation and immunologic recovery in patients with hemat...
- Donor statin treatment protects against severe Acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.
- Salvage allogeneic hematopoietic Cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
- Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic Cell transplantation.
- What is the role for donor natural killer Cells after nonmyeloablative conditioning?
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic Cell transplantation and nonmyeloablative allografting.
- Early recovery of CD4 T Cell receptor diversity after "lymphoablative" conditioning and autologous CD34 Cell transplantation.
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic Cell transplantation following nonmyeloablative conditioning for ...
- Five-year follow-up of patients with advanced chronic lymphocytic Leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- High-dose therapy and autologous stem Cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
- Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin Lymphoma.
- Hematopoietic Cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloab...
- Reduced-intensity conditioning followed by allogeneic hematopoietic Cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disord...
- Nonmyeloablative allogeneic hematopoietic Cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
- Outcomes after allogeneic hematopoietic Cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphoc...
- What is the role of maintenance rituximab in follicular NHL?
- Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with Acute myeloid leukemia in first remission: combined FHCRC and M...
- Comparable outcomes after nonmyeloablative hematopoietic Cell transplantation with unrelated and related donors.
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic Cell transplantation after nonmyeloablative conditioning.
- Comorbidity and disease status based risk stratification of outcomes among patients with Acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic ce...
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic Cell transplantation with nonmyeloab...
- High-dose 131Itositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-Cell transplantation for adults > or = 60 years old with relapsed or refr...
- Nonmyeloablative unrelated donor hematopoietic Cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
- Follicular NHL: from antibodies and vaccines to graft-versus-Lymphoma effects.
- Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.
- Factors associated with outcomes in allogeneic hematopoietic Cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic Cell tran...
- Improving the efficacy of reduced intensity allogeneic transplantation for Lymphoma using radioimmunotherapy.
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear Cell transplantation after nonmyeloablative conditioning: the effect of po...
- Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic Cell transplantation.
- Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
- Modified total body irradiation as a planned second high-dose therapy with stem Cell infusion for patients with bone-based malignancies.
- New treatment options have changed the survival of patients with follicular Lymphoma.
- Hematopoietic Cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
- Immunotherapy for non-Hodgkin's Lymphoma: monoclonal antibodies and vaccines.
- Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic Leukemia.
- Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem Cell transplantation.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid Leukemia.
- Graft-versus-tumor effects after allogeneic hematopoietic Cell transplantation with nonmyeloablative conditioning.
- De novo generation of CD4 T Cells against viruses present in the host during immune reconstitution.
- Comparison of ARF after myeloablative and nonmyeloablative hematopoietic Cell transplantation.
- Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
- Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's Macroglobulinemia.
- Interleukin-7 improves reconstitution of antiviral CD4 T Cells.
- Treatment of follicular non-Hodgkin's Lymphoma.
- Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune Diseases).
- Allogeneic hematopoietic Cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle Cell lymphoma.
- Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic Cell transplantation after nonmyeloablative conditioning.
- Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic Cell transplantation from HLA-matched related donors.
- Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic Cell transplantation after nonmyeloablative and myeloablative conditioning: influence of...
- Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
- Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic Cell transplantation following nonmyeloablative conditioning.
Schools
Stanford University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Stanford University -
Brigham and Women's Hospital
Hospital
-
Seattle Children's Hospital -
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1942385752 | |
| NPPES Provider LastName | MALONEY | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 981950001 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 83.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942385752 |
| Last Name Of The Provider | MALONEY |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Georgiana K. Ellis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Gwin III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith D. Eaton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elihu H. Estey, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Bernardo H. Goulart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio A. Bedalov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey A. Shiovitz, MD |
|
|
Dr. Howard L. West, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larissa A. Korde, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Specht, MD
This Doctor is OpenDoctor Recommended.
|